|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.03 USD | -1.30% |
|
-4.72% | -7.20% |
| Apr. 24 | Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287 | CI |
| Apr. 08 | Gain Therapeutics Names Gene Mack as CFO | MT |
Gain Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 0.05518 million compared to USD 0.140108 million a year ago. Net loss was USD 22.27 million compared to USD 17.59 million a year ago.
Basic loss per share from continuing operations was USD 1.71 compared to USD 1.48 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -7.20% | 49.15M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
GAIN THERAPEUTICS, INC. 
